Development of Compendium for Esophageal Squamous Cell Carcinoma
April 12th, 2024
This protocol describes a useful tool for identifying significant molecular changes in cancer and leads to the development of new diagnostic and therapeutic approaches for esophageal squamous cell carcinoma.
This study is focused on the identification of differentially expressed genes in esophageal squamous cell carcinoma, using open resources such as GEO 2R. In this study, using different bioinformatic tools and techniques, we established that careful rye lab analysis could lead to the identification of a significant number of differentially regulated molecules between cancer and normal conditions.
The literature contains a scattered high throughput data originating using different techniques. And analysis using different tools and techniques further adds to its variation. In the future, we will consider this approach, as well as manual curation to have a robust pipeline for collecting DAMs, including DNA, RNA, protein, metabolite, long non-coding RNAs, micro RNAs, and circular RNAs.
[Instructor] To begin, enter the NCBI web address and click to open it. On the NCBI site, navigate to PubMed, located in the all databases tab on the left sidebar. Enter relevant keywords in the search bar on PubMed to find appropriate articles. Next, access the Geo 2R website. Input the GSE accession number into the Geo accession field, and click on the set button. Create labels, cancer and then normal. To categorize the samples, assign them cancer and normal. Click analyze, keeping all default parameters unchanged. Then access the HPRD page and click on the query button. In the search tab of HPRD, enter either the protein name or its HPRD identifier, and click the search button located at the bottom of the page. Scroll to the bottom of the page and review the localization tab for primary and secondary localizations. To determine the official gene symbol, visit the Hugo Gene Nomenclature Committee, or HGNC website. Enter the gene name obtained from the GEO 2R analysis into the HGNC search bar, and then click on the search icon. Now, to find the gene locus, visit the NCBI website and open the gene page. Enter the official gene symbol in the search bar, and click the search button. Verify the gene and its associated organism in the search results. Then click the link to proceed further. Afterward, access the OMIM page. Input the gene name or symbol for gene phenotype information. Click the search button to find information on the specified gene. The chromosomal distribution of differentially expressed genes on individual chromosomes shows that the maximum numbers of genes were from chromosomes one to six and X. The shiny geo-based pathway analysis identified several important pathways during the analysis of differentially expressed genes.
Overview
This study focuses on identifying differentially expressed genes in esophageal squamous cell carcinoma using open resources like GEO 2R. The findings aim to enhance the understanding of molecular changes in cancer, potentially leading to new diagnostic and therapeutic strategies.
Key Study Components
Area of Science
- Oncology
- Genomics
- Bioinformatics
Background
- Esophageal squamous cell carcinoma is a significant health concern.
- High throughput data from various techniques is often scattered.
- Identifying differentially regulated molecules is crucial for understanding cancer biology.
- Bioinformatic tools can facilitate the analysis of complex datasets.
Purpose of Study
- To identify differentially expressed genes in esophageal squamous cell carcinoma.
- To utilize open resources for comprehensive analysis.
- To establish a robust pipeline for collecting differentially regulated molecules.
Methods Used
- Utilization of GEO 2R for gene expression analysis.
- Application of various bioinformatic tools and techniques.
- Careful lab analysis to identify significant molecular changes.
- Consideration of manual curation for data robustness.
Main Results
- Identification of a significant number of differentially regulated molecules.
- Insights into the molecular landscape of esophageal squamous cell carcinoma.
- Establishment of a framework for future studies on cancer biomarkers.
- Highlighting the importance of integrating various data types.
Conclusions
- This approach can lead to improved diagnostic and therapeutic strategies.
- Future work will focus on refining the pipeline for data collection.
- Collaboration of multiple data sources enhances understanding of cancer biology.
Frequently Asked Questions
Executive Industry Relevance
Integrating high-throughput gene expression data for esophageal squamous cell carcinoma (ESCC) addresses a critical gap in early biomarker discovery and target validation. Standardized pipelines for differential gene expression analysis enable robust identification of disease-relevant molecular signatures, supporting predictive confidence at the earliest stages of oncology R&D. This compendium approach enhances portfolio decision-making by providing a scalable, reproducible framework for biomarker and target nomination across diverse populations.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables systematic interrogation of therapeutic hypotheses through differential gene expression analysis.
- Supports functional target validation by identifying consistently dysregulated genes in ESCC versus normal tissue.
- Facilitates biological de-risking by integrating multi-omic data types for comprehensive pathway analysis.
- Improves predictive confidence for target selection and portfolio triage in oncology programs.
Screening & Assay Development
- Provides a validated set of differentially expressed molecules for downstream assay development.
- Standardizes input data for reproducible screening and quantitative assay outputs.
- Enables scalable preparation of disease-relevant systems for compound evaluation.
- Supports platform reuse by applying the pipeline to additional cancer types or subpopulations.
Translational & Preclinical Research
- Aligns molecular findings with disease-relevant pathways for translational biomarker development.
- Ensures continuity from discovery through preclinical validation by leveraging independent datasets for validation.
- Supports risk-adjusted advancement decisions by clarifying mechanistic underpinnings of ESCC.
- Enhances population-specific target identification for personalized oncology strategies.
Pipeline & Workflow Integration
This pipeline integrates into the discovery continuum from early hypothesis testing through lead identification and preclinical validation, supporting both target nomination and biomarker discovery in ESCC.
- Discovery Biology: Enables hypothesis-driven identification of differentially expressed genes and pathway clarification.
- Screening: Provides reproducible, quantitative gene expression outputs for assay readiness.
- Analytics: Delivers statistical outputs and pathway enrichment analyses to compare disease versus normal conditions.
- Translational Research: Connects molecular findings to preclinical models and biomarker alignment.
- Enterprise Reuse: Offers a reusable analytical framework applicable to other cancer types and datasets.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Drives standardization, reproducibility, and scalability in gene expression analysis workflows.
- Strategic Value: Informs go/no-go decisions and enhances capital efficiency by focusing on validated targets.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of oncology assets.
Implementation Considerations
- Requires expertise in bioinformatics, statistical analysis, and molecular oncology.
- Needs access to high-throughput data repositories and analytical infrastructure.
- Demands cross-team standardization for data preprocessing and normalization.
- Must be adaptable to various omics data types and cancer subtypes.
- Dependent on quality and completeness of public datasets for robust outputs.
